Caldan Therapeutics names new chief executive officer.
M2 PHARMA-March 9, 2017-Caldan Therapeutics names new chief executive officer
(C)2017 M2 COMMUNICATIONS
United Kingdom-based Caldan Therapeutics has named Dr Mark Payton as its chief executive officer, it was reported yesterday.
Dr Payton joins the company from MAPBiotech, where he has served as chief executive officer since 2014. Prior to this, he has been chief executive officer of both Atopix Therapeutics and Oxagen, both based in Oxfordshire, UK, and brings further industry experience from GlaxoSmithKline and Biogen. He co-founded autoimmune disease-focused Orca Pharmaceuticals in 2012, and presently also serves as a senior advisor to The Harrington Project for Discovery and Development.
Dr Liz Roper, partner at Epidarex Capital, which backs Caldan Therapeutics, said, 'We are delighted to welcome Mark on board to lead Caldan Therapeutics moving forward. Continuing to build a strong management team with experienced and talented executives is crucial to building on the science of Professors Milligan and Ulven to deliver new drugs for metabolic diseases.'
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 9, 2017|
|Previous Article:||Bioversys and Aptuit commence joint collaboration to identify and validate novel targets and molecules for Gram-negative bacteria.|
|Next Article:||emotive names Dr Gill Boucher as new medical director.|